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Abstract
Background: Microglia are brain-resident myeloid cells involved in the innate immune response and a variety of
neurodegenerative diseases. In macrophages, TonEBP is a transcriptional cofactor of NF-κB which stimulates the
transcription of pro-inflammatory genes in response to LPS. Here, we examined the role of microglial TonEBP.
Methods: We used microglial cell line, BV2 cells. TonEBP was knocked down using lentiviral transduction of shRNA.
In animals, TonEBP was deleted from myeloid cells using a line of mouse with floxed TonEBP. Cerulenin was used
to block the NF-κB cofactor function of TonEBP.
Results: TonEBP deficiency blocked the LPS-induced expression of pro-inflammatory cytokines and enzymes in
association with decreased activity of NF-κB in BV2 cells. We found that there was also a decreased activity of AP-1
and that TonEBP was a transcriptional cofactor of AP-1 as well as NF-κB. Interestingly, we found that myeloid-
specific TonEBP deletion blocked the LPS-induced microglia activation and subsequent neuronal cell death and
memory loss. Cerulenin disrupted the assembly of the TonEBP/NF-κB/AP-1/p300 complex and suppressed the LPS-
induced microglial activation and the neuronal damages in animals.
Conclusions: TonEBP is a key mediator of microglial activation and neuroinflammation relevant to neuronal
damage. Cerulenin is an effective blocker of the TonEBP actions.
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Introduction
Neuroinflammation is inflammation in the brain or spinal
cord in response to a variety of insults or cues including in-
fection, brain injury, or aging. Like other forms of inflam-
mation, neuroinflammation is mediated by the production
of cytokines, chemokines, reactive oxygen species (ROS),
and secondary messengers [1]. These inflammatory factors
are produced by various cell types in the central nervous
system (CNS) such as microglia, astrocytes, endothelial
cells, other glial cells, and peripherally derived immune
cells. Neuroinflammation can be protective or pathogenic
depending on the context and type of molecules in-
volved [1].
Microglia are resident macrophages of the CNS. During
embryonic development, primitive macrophages generated
in the yolk sac give rise to embryonic microglia [2]. After
birth, bone marrow-derived macrophages cross blood-
brain barrier and supplement the microglial population.
Microglia serve two major functions [3]. Microglia con-
tribute to maintenance of CNS homeostasis by controlling
neuronal proliferation and differentiation. Microglia also
play a critical role in innate immunity in CNS and brain
disease. In settings of pathogenesis, inflammatory stimuli
can prime microglial cell leading to a constant production
of inflammatory cytokines and chemokines which, in turn,
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maintain activation of the primed cells [4]. These cycles fi-
nally lead to neuronal loss and neurodegeneration via in-
flammatory pathways or activation of A1 astrocytes [5, 6].
Tonicity-responsive enhancer binding protein (TonEBP),
also known as nuclear factor of activated T cells 5 (NFAT5),
belongs to the Rel family of transcription factors, which in-
cludes nuclear factor-κB (NF-κB) and NFAT 1–4 [7, 8].
TonEBP is involved in a variety of physiological and patho-
logical processes by controlling transcription of different
sets of genes through distinct mechanisms [9]. For example,
in the renal medulla, TonEBP stimulates transcription of
aquaporin 2 as a cis-acting transcriptional enhancer [10]. In
macrophages, TonEBP regulates transcription of pro-
inflammatory genes such as tumor necrosis factor-α (TNF-
α) and cyclooxygenase-2 (COX-2) as a transcription cofac-
tor of NF-κB independent of DNA binding [11]. As such,
TonEBP is a key regulator of systemic inflammation.
In the brain, TonEBP expression is limited to neurons
without detectable expression in glial cells or other non-
neuronal cells [12]. We recently reported that TonEBP
expression is specifically elicited in microglia in response
to direct injection of lipopolysaccharide (LPS) [13]. Here,
we investigated the role of TonEBP in microglia. Our data
show that TonEBP is a key mediator of microglial activa-
tion and neuroinflammation relevant to neuronal damage.
Methods
Cells in culture
BV2 cells, a mouse microglial cell line (cat. no. CRL-2467,
ATCC) [14], was cultured in Dulbecco’s Modified Eagle’s
Medium (DMEM) containing 5% fetal bovine serum (FBS,
Thermo Fisher Scientific, Inc., MA, USA) and penicillin/
streptomycin (100 U/ml and 100 μg/ml; GE Healthcare
Life Sciences, UT, USA). For HT22 cells, a mouse hippo-
campus neuronal cell line (SCC129) [15] and mouse em-
bryonic fibroblasts (MEFs) cells [11] DMEM containing
10% FBS was used. Cells were maintained at 37 °C in an
incubator with 5% CO2. BV2 cells were transfected with
TonEBP shRNA-harboring lentiviral particles (Santa Cruz
Biotechnology) in the presence of polybrene (5 μg/ml).
Stable cells were selected in the presence of puromycin
(10 μg/ml). Cells were pretreated with cerulenin and BAY
11-7082 (Sigma Aldrich, USA) for 1 h and exposed to
lipopolysaccharide (LPS; Sigma Aldrich).
Immunoblot assay
Cells were washed twice with 1x cold phosphate-
buffered saline (PBS) and lysed in RIPA buffer: 0.01M
Tris, pH 7.4, 0.15M NaCl, 0.001M EDTA, 0.001M
EGTA, 1% Triton X-100, phosphatase inhibitor cocktail
(Sigma Aldrich), and protease inhibitor (Roche, Rotk-
reuz, Switzerland). The lysates were cleared by centrifu-
gation for 15 min at 17,000 g. Protein concentration was
measured by BCA assay (Pierce Biotechnology, IL, USA).
Equal amounts of protein (30 μg) were separated by
SDS-PAGE and immunoblotted with specific primary
antibodies overnight at 4 °C. 1:1000 Anti-c-jun (cat. no.
60A8, Cell Signaling Technologies, Berkeley, CA, USA),
1:1000 p65 (cat. no. D14E12, Cell Signaling Technolo-
gies), 1:1000 COX-2 (cat. no. 4842S, Cell Signaling
Technologies), 1:10000 anti-actin (A5441, Sigma Al-
drich, USA), and 1:3000 anti-TonEBP antibody [7] were
used. 1:10000 HRP-conjugated mouse or rabbit second-
ary antibodies were used for detection. Antigen-antibody
binding was detected by chemiluminescent detection re-
agent (GE Healthcare, NJ, USA).
RNA isolation and quantitative PCR
Total RNA from BV2 cells and mouse hippocampus and
cortex was isolated using TRIzol reagent (Invitrogen,
CA, USA) according to the manufacturer’s instructions.
cDNA was synthesized by M-MLV reverse transcriptase
(Promega). After cDNA synthesis, quantitative PCR was
performed with SYBR Green I Master Mix and a Light-
Cycler 480 II instrument (Roche) using primers shown
in Supplementary Table S1. RNA quantity was normal-
ized to the cyclophilin A mRNA.
ELISA
TNF-α in cell culture media was analyzed by ELISA using a
commercial kit (cat. no. MTA00B, R&D Systems, MN, USA).
MTT assay
1.5 × 106 BV2 cells were seeded in 10ml of culture
medium and grown overnight. The medium was replaced
by 5ml of medium containing 100 ng/ml of LPS, and then,
cultured 24 h to obtain conditioned medium. Each condi-
tioned medium was filtered with a 0.45 μ membrane.
HT22 cells were seeded on 96-well plates at a density of 1
× 104 cells per well with 0.2 ml culture medium. After
overnight culture, the medium was replaced by the micro-
glia conditioned medium. Twenty-four hours later, 20 μl
of 50mg/ml 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltet-
razolium bromide (MTT) was added. Reduced MTT was
measured by absorbance at 490 nm.
TUNEL assay
HT22 cells were plated on coverslips and grown over-
night. The cells were then switched to the microglia-
conditioned medium. After 24 h, TUNEL assay was per-
formed using the DeadEndTM Fluorometric TUNEL Sys-
tem (cat. no. G3250, Promega, WI, USA) following
manufacturer’s instructions.
Luciferase assay
Cells were transfected with either an AP-1 luciferase re-
porter (3xAP1pGL3, www.addgene.org) or a κB-driven
luciferase plasmid [11]. Luciferase activity was measured
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using the Dual-Luciferase Assay System (cat. no. E1910,
Promega) as described [11].
Immunoprecipitation assay
MEF cells were treated without or with 10 μM cerulenin
(Sigma Aldrich) for 1 h followed by a 1 h treatment with
100 ng/ml LPS. Cell lysates were immunoprecipitated
overnight at 4 °C using an anti-c-jun antibody (1:50 dilu-
tion) (Cat. No. 60A8, Cell Signaling Technologies) as de-
scribed previously [11].
Mice
All methods involving live mice were carried out in ac-
cordance with approved guidelines. All experimental
protocols were approved by the Institutional Animal
Care and Use Committee of the Ulsan National Institute
of Science and Technology (UNISTACUC-12-15-A).
TonEBPfl/fl LysM-Cre and TonEBPfl/fl mice described
previously [11] and C57BL/6 J mice were used. The lit-
termates were kept together in the same cage. LysM-Cre
mice were purchased from the Jackson Laboratory (cat.
No. 004781, Bar Harbor, ME, USA). For experiments, 8-
week-old male mice were used.
Stereotaxic surgery
Eight-week-old male mice were anesthetized by intraperi-
toneal injection of zoletil (20mg/kg) and rompun (5mg/
kg). Animals were positioned on a stereotaxic apparatus
and received 3 μl LPS (1 μg/μl 1x PBS) or 1x PBS at a 1 μl/
min rate into the left ventricle (0.6mm posterior; 1.2 mm
lateral; 1.8 mm ventral from bregma) following the previ-
ously reported stereotaxic coordinates [16]. Some animals
received administration of 2mM cerulenin in 3 μl water
(6 nmol) or water alone at a rate of 1 μl/min.
Immunohistochemistry
For immunohistochemistry, mice were anesthetized by
injecting a mixture of zoletil and rompun as described
above. After perfusion with 1x PBS containing 150 mM
NaCl, 60 mM nitrate, and heparin (200u/ml), whole
brain was excised and fixed in 8% paraformaldehyde in
PBS (pH 7.4) at 4 °C. After 1 day, the fixative solution
was replaced with 30% sucrose for an additional 1 day at
4 °C. The fixed brains were cryosectioned at 30 μm and
stored in stock solution containing glycerol, ethylene
glycol, and 0.2M phosphate buffer. For immunofluores-
cence detection, sections were washed twice with 1x PBS
for 15 min and permeabilized with 0.2% Triton X-100 in
BSA/PBS for 1 h. For immunostaining, sections were in-
cubated with 1:500 anti-Iba-1 antibody (cat. no. 019-
19741, Wako, Richmond) or 1:500 anti-NeuN antibody
(cat. no. MAB377, Millipore) in 0.5% BSA/PBS overnight
at 4 °C. Antibody binding was detected with goat anti-
rabbit Alexa Fluor 594 or goat anti-mouse Alexa Fluor
594-conjugated secondary antibodies respectively.
Behavior tests
Passive avoidance test Passive avoidance test was used
to access short-term memory [17]. Passive avoidance ap-
paratus (cat. no. LE872, Panlab) consists of a light and a
dark compartment with an automated sliding door,
across which mice can pass. All the tests were performed
at 1:00 PM which is in resting phase (light period 06:00–
18:00). On day 1 of the experiment, mice were posi-
tioned in the light compartment and allowed 30 s of ex-
ploration. The sliding door was then opened to induce
movement to the dark compartment. This process is re-
peated 3 times for habituation. On day 2 of the experi-
ment, the same protocol was conducted, but entry into
the dark compartment was punished with a mild in-
escapable electrical shock (0.15 mV). On day 3 of the ex-
periment, the procedure was repeated, and the latency
time of each mouse was measured, with a maximum la-
tency time of 5 min. Before each trial, to erase any scent
cues, the interior of the maze was sprayed with 70%
ethanol. All behavioral experiments were conducted over
the same time frame.
Y-maze tests Y-maze test was used to measure spatial
working memory by spontaneous alteration [18–20].
Each mouse was placed in the same arm of the maze
and allowed to move freely for 10 min. The number of
different arm choices and the sequence of choices were
recorded to assess percent alteration. Prior to each trial,
to erase any scent cues, the interior of the maze was
sprayed with 70% ethanol.
Nuclear fractionation
Cell lysates were centrifuged at 500 g. The cell pellet was
washed by suspension with 1x PBS. Nuclear and Cyto-
plasmic extraction kit (cat. no. 78833, Pierce) according
to manufacturer’s instruction was used for separating
the cell nucleus and cytoplasm. Nuclear fraction was
confirmed by Lamin B.
Statistical analysis
Data are expressed as the mean + SD or SEM. Statistical
significance was estimated using one-way ANOVA or
two-way ANOVA with Tukey’s post hoc test for multiple
comparisons where applicable. All statistical analyses were
performed using the GraphPad Prism 5.0 software
(GraphPad, CA, USA).
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Results
TonEBP is required for inflammation in BV2 cells
In macrophages [11] and hepatocytes [21], TonEBP is a key
component of transcriptional machinery for pro-
inflammatory gene expression in response to LPS and other
signals. TonEBP expression increases dramatically in re-
sponse to LPS in microglia in association with increased
iNOS mRNA expression [13] as in macrophages and hepa-
tocytes. We asked what was the role of TonEBP in LPS-
stimulated expression of pro-inflammatory genes in micro-
glia. To answer this question, we first examined a glial cell
line BV2 cells. TonEBP expression increased in response to
LPS treatment (Fig. 1a) as in microglia discussed above.
iNOS expression also increased in association with elevated
levels of nitrite which is a degradation product of nitric
oxide (Fig. 1b). The increased iNOS expression was associ-
ated with elevation of iNOS mRNA levels along with
mRNA levels for other pro-inflammatory enzyme and cyto-
kines—COX-2, TNF-α, IL-1β, and IL-6 (Fig. 1c). As ex-
pected from the elevated mRNA levels, expression of COX-
2 and production of TNF-α also increased (Fig. 1 a and d).
When TonEBP was knocked down using lentivirus, mRNA
and protein product of the pro-inflammatory enzymes and
cytokines all decreased (Fig. 1a–d) indicating a critical role
of TonEBP in BV2 cells as in macrophages and hepatocytes.
Activated microglia are known to secrete toxic mole-
cules such as reactive oxygen species including nitric
oxide, prostaglandin E2, and cytokines that kill neuronal
Fig. 1 TonEBP in LPS-induced inflammation in BV2 cells. BV2 cells were stably transfected using lentivirus containing empty shRNA (open bars in
b–e) or TonEBP targeting shRNA (solid bars in b–e) as indicated. a The cells were then treated for 24 h with 0 to 100 ng/ml of LPS as indicated
and immunoblotted for TonEBP, iNOS, COX-2, and β-actin as shown in left. Right panels show band intensity for TonEBP, iNOS, and COX-2
corrected by intensity of corresponding β-actin band. b Nitrite was measured in the media of cells treated for 24 h with 0 (CTL:1x PBS) or 10 ng/
ml LPS using Griess reagent. c RT-qPCR was performed on cells treated for 1 h (for TNF-α and IL-1β) or 6 h (for iNOS, COX-2, and IL-6) with LPS as
in b. d TNF-α was measured in the medium after the cells were treated for 6 h with LPS. e The stably transfected cells were treated for 24 h with
0 (CTL:1x PBS) or 100 ng/ml LPS to obtain conditioned media. HT22 cells grown in regular medium were switched to the conditioned media.
After 24 h, cell viability was measured using MTT assay. Mean + SD, n = 3. *P < 0.05 compared to empty shRNA. #P < 0.05 compared to CTL
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cells [22]. We found that LPS stimulation of microglia
produced neurotoxins as measured by reduced survival
of a neuronal cell line HT22 cells (Fig. 1e) that might be
due to the secretion of neurotoxins by microglia. The
production of neurotoxins was reduced in TonEBP-
deficient BV2 cells consistent with the reduced produc-
tion of inflammatory cytokines.
Cerulenin blocks LPS-induced inflammation by disrupting
TonEBP interaction with NF-κB and AP-1
In macrophages and hepatocytes, TonEBP is central
scaffold in the assembly of NF-κB enhanceosome in
which TonEBP connects DNA-bound NF-κB to the his-
tone acetyl transferase p300 [11]. Cerulenin inhibits NF-
κB actions by breaking up the assembly of the NF-κB
enhanceosome. We used cerulenin to ask whether the
NF-κB enhanceosome was responsible for the pro-
inflammatory gene expression in BV2 cells. As shown in
Fig. 2, cerulenin inhibited mRNA expression and protein
expression of the pro-inflammatory enzymes and
cytokines demonstrating that the NF-κB enhanceosome
was responsible for the transcriptional stimulation. In
addition, cerulenin showed clear inhibition on mRNA
expression and nitrite production under basal conditions
(without LPS treatment).
Cell death by the conditioned media was reduced by
cerulenin (Fig. 3a) as might be expected from the re-
duced production of cytokines. In order to exclude the
possibility that the presence of cerulenin in the condi-
tioned media was responsible for the reduced neurotoxic
activity, cerulenin was directly added to the LPS-
conditioned medium (Fig. 3b). The presence of cerulenin
did not affect neurotoxic activity indicting that cerulenin
in the medium was not responsible for the reduced
neurotoxic activity. Since the neurotoxic activity was due
to cell death by apoptosis [23], we examined apoptosis
in the HT22 cells treated with the conditioned medium.
The LPS-conditioned media stimulated apoptosis dra-
matically (Fig. 3c). On the other hand, conditioned
media obtained from BV2 cells treated with LPS in the
presence of cerulenin caused much less apoptosis indi-
cating that products of the pro-inflammatory genes were
responsible for the neuronal death.
We noticed that the production of potential neurotoxins
was also inhibited by an NF-κB inhibitor BAY11-7092 as
expected (Fig. 3a). Activity of an NF-κB reporter was
Fig. 2 Cerulenin inhibits LPS-induced inflammation in BV2 cells. a The cells were pretreated for 1 h with 10 μM cerulenin (solid bars in b–d) or
vehicle (water) (open bars in b–d), followed by a 24 h treatment with 0 (CTL:1x PBS) or 10 ng/ml of LPS. Immunoblotting and quantitation were
performed as in Fig. 1. b Nitrite was measured from the media of cells treated as above except that LPS treatment was for 24 h. c RT-qPCR was
performed on cells treated as in b except that LPS was treated for 1 h (for TNF-α and IL-1β) or 6 h (for iNOS, COX-2, and IL-6). d TNF-α was
measured in the medium after the cells were treated as in b for 6 h with LPS. Mean + SD, n = 3. *P < 0.05 compared to vehicle. #P < 0.05
compared to CTL
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stimulated by LPS, which was completely blocked by
cerulenin (Fig. 4a), consistent with the role of the
NF-κB enhanceosome in BV2 cells. Interestingly, we
found that an AP-1 reporter was also stimulated by
LPS, which was blocked by cerulenin (Fig. 4b). Since
AP-1 is activated by LPS and contributes to pro-
inflammatory gene expression like NF-κB does [24],
we wondered if TonEBP also functioned as a tran-
scriptional cofactor for AP-1. In order to directly test
this possibility, we performed co-immunoprecipitation
analyses to detect interaction between AP-1 and
TonEBP as described previously [11]. When c-jun, a
subunit of AP-1, was immunoprecipitated, TonEBP
was also brought down (Fig. 4c) demonstrating the
interaction between TonEBP and AP-1. Since TonEBP
also interacts with p300 in this setting [11], these
data provide evidence that TonEBP is a transcrip-
tional cofactor for AP-1. Of note, the interaction was
reduced in the presence of cerulenin suggesting that
cerulenin disrupted the interaction between TonEBP
and AP-1 (Fig. 4c) as it disrupts the interaction be-
tween TonEBP and NF-κB [11]. Cerulenin does not
change phosphorylation and translocation of NF-κB
[11]. Likewise, we found no changes in phosphoryl-
ation and nuclear translocation of c-jun (a subunit of
AP-1) by treatment of cerulenin (Supplementary Fig.
S2) consistent with disruption of the interaction of
TonEBP with AP-1 as well as NF-κB. Since there are
AP-1 binding sites as well as NF-κB binding sites in
the promoter regions of the pro-inflammatory genes
[25–27], the TonEBP’s transcriptional cofactor func-
tion for both AP-1 and NF-κB is consistent with the
cerulenin’s strong inhibition shown in Figs. 2 and 3.
TonEBP mediates LPS-induced microglial activation
In order to directly assess the role of TonEBP in micro-
glial activation in response to LPS, myeloid-specific
TonEBP gene deletion was used. We crossed a floxed
TonEBP line (TonEBPfl/fl) with a transgenic line with cre re-
combinase expression under the control of lysozyme
Fig. 3 Cerulenin blocks LPS-induced secretion of neurotoxins by BV2 cells. a BV2 cells were pretreated for 1 h with vehicle (0.01% DMSO), 10 μM
cerulenin, or 5 μM BAY11-7082, followed by treatment for 24 h with 0 (CTL:1x PBS) or 100 ng/ml LPS to obtain conditioned media. HT22 cells
grown in regular medium were switched to the conditioned media. After 24 h, cell viability was measured using MTT assay. b HT22 cells were
cultured in various microglia-conditioned media (MCM) shown with or without addition of 10 μM cerulenin as indicated. Cell viability was
measured as above. V, vehicle, C, cerulenin. c HT22 cells grown on chamber slides were treated as in a: pretreatment with vehicle or cerulenin
followed by treatment with CTL or LPS. Fixed cells were analyzed by TUNEL assay. Nuclei were visualized with DAPI. Percent of TUNEL positive
cells are shown on the right. Two-way ANOVA with Tukey’s post hoc test was used for multiple comparisons. Bar = 200 μm. Different letters
indicate statistical differences at P < 0.05. Mean + SD, n = 3-4. *P < 0.05, compared to vehicle in c. #P < 0.05 compared to CTL in c
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promoter (LysM-Cre) to produce TonEBPfl/fl LysM-Cre
mice [11]. Efficiency of microglial gene deletion in the
LysM-Cre line is reported to be 90% [28]. Eight-week-old
male TonEBPfl/fl LysM-Cre mice and their TonEBPfl/fl litter-
mates were used for experiments. To induce inflammation
of the brain, we performed intracerebroventricular injection
of LPS as described [13]. Cortex (CTX) and hippocampus
(HIP) were processed for immunostaining and RNA
analysis 3 h after LPS injection. Microglial activation was
detected by immunohistochemical visualization of Iba-1, a
marker for activated microglia [29]. Based on increased area
of Iba-1-positive area and number of Iba-1-positive cells,
LPS injection resulted in a clear activation of microglia in
the TonEBPfl/fl animals (Fig. 5a). The activation was associ-
ated with elevated levels of mRNA for TNF-α and IL-1β
(Fig. 5b). Both the microglial activation and elevation of
mRNA levels were blocked in the animals with myeloid-
specific TonEBP deletion, i.e., in the TonEBPfl/fl LysM-Cre
animals. These data demonstrate that myeloid TonEBP is
required for inflammatory microglial activation.
Next, we asked whether TonEBP-dependent actions of
NF-κB and AP-1 were involved in the microglial activa-
tion. Cerulenin was injected into the brain 1 h prior to
LPS injection described above. Cerulenin blocked the acti-
vation of microglia (Fig. 6a) and the increased expression
of mRNA for TNF-α and IL-1β (Fig. 6b). These data show
Fig. 4 Cerulenin inhibits AP-1 transcriptional activity by disrupting its interaction with TonEBP. a BV2 cells were transfected with an NF-κB
luciferase reporter. Luciferase activity was measured 3 h after treatment with 100 ng/ml LPS or vehicle (CTL:1x PBS). Where indicated, some cells
were pretreated for 1 h with 10 μM cerulenin before treatment with LPS. Mean + SD, n = 3. #P < 0.05, compared to LPS. *P < 0.05 compared to
CTL. b BV2 cells were transfected with an AP-1 luciferase reporter. Luciferase activity was measured 3 h after treatment with 100 ng/ml LPS or
vehicle (CTL:1x PBS). Where indicated, some cells were pretreated for 1 h with 10 μM cerulenin before treatment with LPS. Mean + SD, n = 4. #P <
0.05, compared to LPS. *P < 0.05 compared to CTL. c MEF cells were pretreated with cerulenin (C) or vehicle (V) followed by treatment with LPS
as above. Cell lysates were immunoprecipitated using c-jun antibodies and then immunoblotted for TonEBP and c-jun as shown in left. Right
panel shows band intensity for TonEBP corrected by intensity of corresponding c-jun band. **P < 0.05 compared to vehicle. #P < 0.05 compared
to CTL
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that TonEBP mediates microglial activation by stimulating
the transcriptional activity of NF-κB and AP-1.
TonEBP mediates LPS-induced memory loss in association
with reduced number of neuronal cells
Since TonEBP mediates LPS-induced neuroinflamma-
tion (see above) and neuroinflammation induces
memory loss [30, 31], we asked whether TonEBP is
required from LPS-induced memory loss. The male
TonEBPfl/fl LysM-Cre mice and their TonEBPfl/fl lit-
termates were injected with LPS or vehicle as de-
scribed above. Two weeks later, passive avoidance
test was performed to assess short-term memory
followed by histological analysis of the brains. Short-
term memory measured by latency in passive avoid-
ance test was halved in the TonEBPfl/fl mice (Fig. 7a)
in association with reduced number of neurons in
the CA3 region of the hippocampus (Fig. 7b). The
reduced neuronal cell number was likely due to cell
death as observed in BV2 cells whose TonEBP was
knockdown (Fig. 1e). These changes were not ob-
served in the TonEBPfl/fl LysM-Cre mice suggesting
that TonEBP is required for the LPS-induced neur-
onal cell death and memory loss.
Fig. 5 Myeloid TonEBP is required for LPS-induced microglia activation. LPS (3 μg per animal) or vehicle (CTL:1x PBS) was injected into the left
ventricle of male TonEBPfl/fl,LysM-cre mice (solid bars) and their TonEBPfl/fl littermates (open bars). Brains were analyzed 3 h later. a Brains were
perfusion-fixed and immunostained for iba-1. Images from cortex (CTX) and hippocampus (HIP) (top) were analyzed for iba-1 positive areas and
iba-1 positive cell numbers (bottom). Bar = 70 μm. b RNA was isolated from CTX and HIP, and analyzed by RT-qPCR for TNF-α and IL-1β. Mean +
SE, n = 3–6. #P < 0.05, compared to CTL. *P < 0.05 compared to TonEBP fl/fl
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In order to examine the role of TonEBP-mediated
actions of NF-κB and AP-1, we examined the effects
of cerulenin. LPS or vehicle was injected into the
brain of 8-week male mice as described above. Y-
maze test was performed after 1 week to assess spatial
memory, and passive avoidance test after 2 weeks as
described above (Fig. 8a). In animals injected with
LPS, both spatial memory and short-term memory
were significantly reduced (Fig. 8b, c) in association
with reduced number of neurons in the CA3 region
of the hippocampus (Fig. 8d). These changes were
blocked when cerulenin was pretreated 1 h before the
LPS administration suggesting that TonEBP-mediated
neuroinflammation causes neuronal cell death and
memory loss. (Supplementary Fig. 1)
Discussion
The activation of microglia contributes to aging [32, 33]
and the pathogenesis of neurodegenerative diseases such
as Alzheimer’s disease [34–36]. NF-κB and AP-1 are es-
sential transcriptional regulators for the activation of
microglia [37–39] as well as for pro-inflammatory activa-
tion of macrophages [40, 41]. In macrophages, TonEBP
is a key mediator of LPS-induced activation of pro-
inflammatory gene expression [11, 42, 43]. This is
achieved in two ways: elevation of TonEBP expression
Fig. 6 Cerulenin inhibits LPS-induced microglia activation. Cerulenin (6 nmol per animal, solid bars) or vehicle (water) (open bars) was injected
into the left ventricle. One hour later, LPS (3 μg per animal) or vehicle (CTL:1x PBS) was injected again. Brains were analyzed 3 h later. a Brains
were perfusion-fixed and immunostained for iba-1. Images from cortex (CTX) and hippocampus (HIP) (top) were analyzed for iba-1 positive area
and iba-1 positive cell number (bottom). Bar = 70 μm. b RNA was isolated from CTX and HIP and analyzed by RT-qPCR for TNF-α and IL-1β. Mean
+ SE, n = 3–4. #P < 0.05, compared to CTL. #P < 0.05, compared to CTL. *P < 0.05 compared to vehicle
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and TonEBP functioning as transcriptional cofactor
for NF-κB. Here, we find that TonEBP has the same
role in microglia. In addition, we discover that
TonEBP is also the transcriptional cofactor for AP-1.
In settings of LPS-induced microglial activation and
neuronal damage, the TonEBP-mediated actions of
AP-1 and NF-κB are required for the inflammatory
activation of microglia based on observations from
TonEBP deleted animals and effects of cerulenin,
which inhibits AP-1 and NF-κB by blocking their in-
teractions with TonEBP and p300. Thus, TonEBP me-
diates the LPS-induced microglial activation and
neuronal damage as transcriptional cofactor for AP-1
and NF-κB, which are the major transcription factors
in the pro-inflammatory gene expression.
Neuroinflammation is associated with aging [44, 45],
metabolic diseases [46], and a variety of neurodegenerative
diseases such as Alzheimer’s disease [47, 48], Parkinson’s
disease [49], multiple sclerosis [50], and amyotrophic lat-
eral sclerosis [51]. Various causes including obesity, dia-
betes, hypertension, and even lifestyles increase systemic
inflammatory response [52, 53]. Systemic increase in pro-
inflammatory mediators (cytokines, chemokines, ROS,
and secondary messengers) enhances microglial cell acti-
vation [53], which makes neuroinflammation as a disease-
promoting factor in neurodegenerative diseases. The acti-
vated microglia cause neuronal death via inflammatory
factors, A1 astrocyte activation, and microglia-mediated
synapse loss [5, 6]. Our data presented here uncovers the
role of microglial TonEBP in neuronal death. Targeting
Fig. 7 Myeloid TonEBP is required for blocking LPS-induced loss of short-term memory. a LPS (3 μg per animal) or vehicle (CTL:1x PBS) was
injected into the left ventricle of male TonEBPfl/fl,LysM-cre mice (KO in b) and their TonEBPfl/fl littermates (WT in b). Two weeks later, passive
avoidance test was performed followed by perfusion fixation of the brains. Latency in seconds in passive avoidance test. Mean + SE, n = 3–6. *P
< 0.05 B NeuN immunostaining in CA3 region of hippocampus. Florescence intensity of the immunostaining was shown on the right. Bar =
50 μm. Mean + SE, n = 3. #P < 0.05, compared to CTL. *P < 0.05 compared to TonEBP fl/fl
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the TonEBP/AP-1/NF-κB pathway should be an attractive
strategy to prevent the neuronal death. In this regard, the
actions of cerulenin in inhibiting the prototypical pro-
inflammatory transcription factors AP-1 and NF-κB by
disrupting their interactions with TonEBP rather than dir-
ect inhibition (such as nuclear translocation or phosphor-
ylation) provide a new mode of intervention and potential
therapeutics.
Conclusions
In sum, this study has shown that TonEBP is required for
the LPS-induced microglial activation and pro-
inflammatory gene expression. TonEBP mediates the tran-
scriptional activity of the classical pro-inflammatory tran-
scription factors NF-κB and AP-1. Deletion of TonEBP in
myeloid cells or treatment with cerulenin blocks the
TonEBP-mediated activation of NF-κB and AP-1, microglial
activation, and subsequent neuronal damages. Thus, we
have delineated intracellular pathways involved in the
microglial activation relevant to neuronal damage.
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